title: Efficacy of quick-release lornoxicam versus placebo for acute pain management after dental implant surgery: a randomised placebo-controlled triple-blind trial.
abstract: OBJECTIVE
  To assess the efficacy of quick-release lornoxicam (LNX) on patient-reported acute pain after dental implant surgery.
  
  
  METHODS
  The study included subjects in good general health, aged 18 to 65 and scheduled to receive a maximum of three implants in the same quadrant. Participants received either 8 mg LNX or placebo and were asked to use the medications in case of pain in the first 120 min after implant surgery. Assessment of efficacy was performed using self-assessment questionnaires for the evaluation of pain intensity and pain relief for 12 h post dosing. Patients were also asked to record the rescue analgesic number. Evaluation of patient satisfaction was assessed using a 7-point scale. Safety was evaluated by the incidence of adverse events.
  
  
  RESULTS
  A total of 83 (LNX/placebo, 42/41) patients who met the inclusion criteria and finished the evaluation period were included in the study. The proportion of patients experiencing postoperative pain was significantly lower in the LNX-treated group compared to the placebo group. Patients in the LNX group reported significantly higher pain relief scores than the placebo group. Twenty-nine patients in the placebo group and 6 patients in the LNX group used rescue analgesics. The number of used rescue analgesics was 1.024 ± 0.79 and 0.167 ± 0.43 in the placebo and LNX groups, respectively. The level of patient satisfaction was significantly higher in the LNX-treated patients (P = 0.007). No adverse events were reported during the study period.
  
  
  CONCLUSIONS
  Quick-release LNX is effective in postoperative acute pain control and has a high safety profile following dental implant surgery.
authors.affiliation: Istanbul University, Faculty of Dentistry, Department of Oral Implantology, Istanbul, Turkey.
authors.forename: Nilüfer
authors.initials: N
authors.lastname: Bölükbasi
authors.forename: Selim
authors.initials: S
authors.lastname: Ersanli
authors.forename: Cansu
authors.initials: C
authors.lastname: Basegmez
authors.forename: Tayfun
authors.initials: T
authors.lastname: Ozdemir
authors.forename: Süleyman
authors.initials: S
authors.lastname: Ozyalcin
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003758:Dental Implantation, Endosseous / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010149:Postoperative Pain / Q000188:drug therapy* / Q000209:etiology; D017060:Patient Satisfaction; D010894:Piroxicam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D057566:Self Report; D018709:Statistics, Nonparametric
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C059451:lornoxicam